Hainanhaiyao's Novel Anti-Hepatic Fibrosis Drug Completes Phase II Trial

Stock News

06/24

Hainanhaiyao Co.,Ltd. (SHE: 000566) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now progressing as scheduled.

Concurrently, the company's novel anti-epileptic drug, Paienjiabin Tablets, has concluded its Phase IIa trial, and the Phase IIb clinical trial is advancing according to plan.

The company highlights that new drug development is characterized by long cycles, substantial investment, and high risks. The clinical trial process and outcomes involve numerous uncertainties, and there is no guarantee of subsequent regulatory approval for market launch. These developments are not expected to have a significant impact on the company's financial performance in the short term.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1106638512"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106638512\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106638512?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106638512","market":"hk","top_or_hot":-1,"title":"Hainanhaiyao's Novel Anti-Hepatic Fibrosis Drug Completes Phase II Trial","media":"Stock News","content":"<p><b>Hainanhaiyao Co.,Ltd.</b> (<b>SHE: 000566</b>) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now progressing as scheduled.<br><br>Concurrently, the company's novel anti-epileptic drug, Paienjiabin Tablets, has concluded its Phase IIa trial, and the Phase IIb clinical trial is advancing according to plan.<br><br>The company highlights that new drug development is characterized by long cycles, substantial investment, and high risks. The clinical trial process and outcomes involve numerous uncertainties, and there is no guarantee of subsequent regulatory approval for market launch. These developments are not expected to have a significant impact on the company's financial performance in the short term.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hainanhaiyao's Novel Anti-Hepatic Fibrosis Drug Completes Phase II Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHainanhaiyao's Novel Anti-Hepatic Fibrosis Drug Completes Phase II Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-06-24 21:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>Hainanhaiyao Co.,Ltd.</b> (<b>SHE: 000566</b>) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now progressing as scheduled.<br><br>Concurrently, the company's novel anti-epileptic drug, Paienjiabin Tablets, has concluded its Phase IIa trial, and the Phase IIb clinical trial is advancing according to plan.<br><br>The company highlights that new drug development is characterized by long cycles, substantial investment, and high risks. The clinical trial process and outcomes involve numerous uncertainties, and there is no guarantee of subsequent regulatory approval for market launch. These developments are not expected to have a significant impact on the company's financial performance in the short term.<br><br></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"000566","symbol_name":"海南海藥","start_time":0,"source_url":"","article_id":"1106638512","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106638512","pubTimestamp":1782306681,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hainanhaiyao Co.,Ltd. (SHE: 000566) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","000566":"海南海药","BK0146":"智慧医疗","BK0239":"医药制造","06978":"永泰生物-B","BK1161":"生物科技","BK0070":"员工持股","BK0188":"融资融券","BK1574":"生物医药B类股","BK0060":"抗癌"},"translate_title":"海南海药抗肝纤维化新药完成II期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"000566":1},"content_text":"Hainanhaiyao Co.,Ltd. (SHE: 000566) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now progressing as scheduled.Concurrently, the company's novel anti-epileptic drug, Paienjiabin Tablets, has concluded its Phase IIa trial, and the Phase IIb clinical trial is advancing according to plan.The company highlights that new drug development is characterized by long cycles, substantial investment, and high risks. The clinical trial process and outcomes involve numerous uncertainties, and there is no guarantee of subsequent regulatory approval for market launch. These developments are not expected to have a significant impact on the company's financial performance in the short term.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}